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There is a pressing need to develop novel, mechanism-based therapeutic approaches that can be used to
improve therapies for genetically defined tumor subtypes. Chan and colleagues have demonstrated recently
that BCL-2 inhibitors can target IDH1/2mutant cancers through a mutant-specific dependency in metabolic
regulation.Our increasing knowledge of the somatic
cancer genome has led to the develop-
ment of molecularly targeted therapies
for an ever-expanding list of cancer sub-
types. This has included the development
of tyrosine kinase inhibitors for hemato-
logic and epithelial tumors, which have
had a substantive clinical impact. How-
ever, there has been an increasing
interest in the development of genotype-
specific targeted therapies that do not
target mutated proteins themselves, but
rather leverage mutant-specific depen-
dencies in a specific genomic context.
In a recent issue of Nature Medicine,
Chan et al. (2015) elucidate a critical
role of IDH1/2 mutations in deregulating
mitochondrial function with therapeutic
implications and suggest that BCL-2
inhibitors can target IDH1/2 mutant
cancers.Isocitrate dehydrogenases (IDHs) cata-
lyze the oxidative decarboxylation of
isocitrate to a-ketoglutarate (a-KG) and
NADPH during the citric acid cycle. Muta-
tions in IDH1 were first identified through
exome sequencing in colorectal cancer
(Sjo¨blom et al., 2006). Shortly thereafter,
recurrent IDH1 and IDH2 mutations were
found in glioma and acute myeloid leuke-
mia (AML) (McKenney and Levine, 2013).
The most common IDH1 and IDH2 muta-
tions in AML affect arginine residues,
R132 of IDH1 protein, or R140 and R172
of IDH2. Of note, metabolomics and
biochemical studies have shown that
the mutant enzymes gain a neomorphic
activity that catalyzes the conversion
of a-KG to (R)-2-hydroxyglutarate [(R)-
2HG]. (R)-2HG may act as an onco-
metabolite by inhibiting the function
of a-KG-dependent enzymes, includingTET family enzymes, Jumonji-C domain
containing proteins, and other critical reg-
ulators of the epigenetic state (Xu et al.,
2011). As a consequence, these muta-
tions can result in dysregulated angiogen-
esis, alterations in the pattern of histone
modifications, and aberrant DNA methyl-
ation (Krell et al., 2013).
In addition to their impact on the epige-
netic state, several studies have sug-
gested that IDH1/2 mutations can alter
global cellular metabolism and that
these alterations in metabolic milieu can
contribute to oncogenic transformation.
Reitman and Yan (2010) noted depletion
of the tricarboxylic acid (TCA) cycle
metabolites citrate, cis-aconitate, a-KG,
malate, and fumarate and an accumu-
lation of biosynthetic precursors in cell
lines that expressed IDH1 R132H and
IDH2 R172K mutations, suggesting that27, March 9, 2015 ª2015 Elsevier Inc. 323
IDH mutant cells
Plasma membrane
Mitochondria
Complex III Complex IV
Matrix
Intermembrane
Space
H+ H+ H+ H+
Cytochrome c
O2
H2O
IDH mutant cells
+ ABT-199
IDH1/2mut
(R)-2HG
BCL-2
isocitrate
Plasma membrane
Mitochondria
Complex III Complex IV
Matrix
Cytochrome c
O2
H2O
(R)-2HG
BCL-2
BAX/BAK
isocitrate
BAX/BAK
APOPTOSIS
ABT-199
A B
BAX/BAK IDH1/2mut
Intermembrane
Space
Figure 1. Synthetic Lethal Mechanism between IDH1/2 Mutations and BCL-2: Definition of a New Therapeutic Target
(A) (R)-2HG, generated by IDH1/2 mutants, inhibits cytochrome c release by complex IV (COX), which activates BAX/BAK signaling that is blocked by BCL-2
activity, allowing cell survival.
(B) ABT-199 treatment of IDH1/2-mutated cells permits full activation and oligomerization of BAX/BAK proteins, resulting in mitochondrial outer membrane
permeabilization (MOMP)-induced apoptosis.
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Previewsthese mutations can result in TCA cycle
downregulation. Furthermore, (R)-2HG
may impair the mitochondrial respiratory
chain through inhibition of cytochrome c
oxidase and ATP synthase (Latini et al.,
2005). However, the therapeutic relevance
of these findings was not fully delineated.
Chan et al. (2015) performed a high
content small hairpin RNA (shRNA) screen
in isogenic leukemia cells expressing
wild-type and mutant IDH1 and found
that the survival of IDH1/2 mutant cells
was highly dependent on expression of
the BCL-2 family members: BCL-2 and
BCL-W (Chan et al., 2015). The authors
then demonstrated a strong association
between IDH1/2 mutational status and
BCL-2 family dependence in cell line sys-
tems and patient samples.
Most importantly, these observations
suggested a near-term therapeutic op-
portunity. Anti-apoptotic BCL-2 family
proteins antagonize death signaling by324 Cancer Cell 27, March 9, 2015 ª2015 Elsforming heterodimers with pro-death
proteins, including BAX and BAK. Hetero-
dimer formation occurs through binding
of the pro-apoptotic protein’s BH3domain
into thehydrophobiccleft of anti-apoptotic
proteins. This insight led to the develop-
ment of small molecule BH3 mimetics
that function as competitive inhibitors of
BCL-2 by binding to the hydrophobic
cleft (Ni Chonghaile and Letai, 2008). As a
highly specific BCL-2 inhibitor, ABT-199
is in late phase clinical trials in chronic
lymphocytic leukemia and other lymphoid
neoplasms. The authors therefore investi-
gated the sensitivity of IDH1/2 mutant
andwild-type AML cells to ABT-199. Con-
sistent with their genetic data, AML cells
expressingmutant IDH1/2weremore sen-
sitive to ABT-199 compared to wild-type
cells. More importantly, studies using
patient-derived xenografts confirmed the
in vitro studies, because IDH1/2 mutant
AML cells were sensitive to BCL-2 inhibi-evier Inc.tion with ABT-199 in vivo. They also noted
an impact of ABT-199 therapy on second-
ary transplantation assays, suggesting
that IDH1/2 mutant leukemia stem cells
were also sensitive to ABT-199. These
data underscore the potential therapeutic
relevance of their observation, which can
be tested in the clinical context.
Next Chan et al. (2015) investigated
the mechanism involved in IDH1/2 muta-
tions’ dependency on BCL-2 family
members in AML cells. They first demon-
strated that culturing wild-type IDH1/2
leukemic cell lines or primary AML blasts
with octyl-(R)-2HG, a cell-permeable pre-
cursor of (R)-2HG, could confer BCL-2
dependence. These data suggested the
neomorphic activity of mutant IDH1/2
proteins was responsible for conferring
BCL-2 dependence in AML cells. They
then elucidated how IDH1/2 mutations
altered the balance between pro-
apoptotic and anti-apoptotic members’
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Previewsexpression. In homeostatic conditions,
BAX and BAK initiate apoptosis by
causing mitochondrial outer membrane
permeabilization, leading to cytochrome
c release in the cytosol and collapse
of the mitochondrial transmembrane
potential (DJmito) (Souers et al., 2013).
The authors used the membrane-perme-
ant JC-1 dye as an indicator of mito-
chondrial membrane potential and found
that ABT-199 treatment of IDH1/2 mutant
cells or cells exposed to octyl-(R)-2HG
resulted in a collapse ofDJmito. The effect
of 2HG was enantiomer specific, because
treatment with (S)-2HG had no impact on
the time of mitochondrial transmembrane
potential collapse. Mitochondrial studies
showed that (R)-2HG had a specific effect
on the activity of complex IV (also known
as COX) enzymatic activity. Previous
studies described that D-2-hydroxy-
glutaric acid (DGA) could inhibit complex
IV activity and, to a lesser extent, complex
V activity in muscular tissues (Latini et al.,
2005). Consistent with these studies, the
authors found that COX activity is also
decreased in primary IDH1/2mutant cells
without any change in the mitochondrial
mass present in the cells.
Consistent with their in vitro and
preclinical models, IDH1/2 mutations,
through (R)-2HG accumulation, maypromote oncogenesis through their effect
on mitochondrial respiration and pro-
mote dependence on BCL-2 for survival
(Figure 1A). The observation that IDH1/2
mutations confer sensitivity to ABT-199
may serve as eligibility criteria for ABT-
199 trials in IDH1/2 mutant leukemias
and other IDH1/2 mutant tumor types
(Figure 1B). Moreover, these findings
may have relevance for cancers without
IDH1/2 mutations. Specifically, the au-
thors demonstrated that COX inhibitors
decrease mitochondrial respiration and
promote sensitivity to ABT-199, suggest-
ing the possibility of combined electron
transport chain and BCL-2 inhibition as
a therapeutic approach in cancer. More-
over, this study highlighted the impor-
tance of mitochondrial dysfunction in
this AML subtype and will lead to subse-
quent studies of metabolic vulnerabilities
in AML and other cancers.
Most importantly, these studies provide
a strong rationale for investigating the
efficacy of BCL-2 inhibition in IDH1/2
mutant cancer and add to the expanding
armamentarium of targeted cancer thera-
pies for this genetically defined cancer
subset. Taken together, these discoveries
provide new hope for patients with IDH
mutant malignancies and provide a
clarion example of how functional studiesCancer Cellcan be used to nominate novel, genotype-
specific therapies.REFERENCES
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